Cell and gene therapies often originate at small biopharmaceutical firms, but big pharma and large biotech companies continue to increase their investments in these new modalities when they see external innovations that fit within their research and development strategies. Therapeutic area priorities and unmet needs drive these business development decisions, according to executives from Janssen, Biogen, Inc. and Astellas Pharma, Inc.
Sanjaya Singh, vice president and global head at Janssen BioTherapeutics and Janssen Research & Development LLC (subsidiaries of Johnson...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?